{"nctId":"NCT01590797","briefTitle":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","startDateStruct":{"date":"2012-07-10","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":467,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Biological: Insulin","Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Biological: Insulin","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia®","MK-0431"]},{"name":"Placebo","otherNames":[]},{"name":"Insulin","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has T2DM\n* is currently on a stable regimen of pre-mixed, intermediate-acting, or long-acting insulin at a dose of at least 12 U/day, either alone or in combination with metformin \\>=1500 mg/day for ≥ 10 weeks\n* has a Visit 1/Screening HbA1C between 7.5% and 11.0%\n* is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication\n\nExclusion Criteria:\n\n* has been treated with any antihyperglycemic therapies other than a protocol-required insulin (alone or with metformin) within the prior 12 weeks or has ever\n\nbeen treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue\n\n* is currently on treatment with daily use (one or more injections per day) of\n\npre-prandial short-acting or rapid-acting insulin\n\n* has a history of 2 or more episodes of hypoglycemia resulting in seizure,\n\ncoma, or loss of consciousness, or has had recurrent episodes of hypoglycemia over the past 8 weeks\n\n* has a history of intolerance or hypersensitivity, or has any contraindication to sitagliptin, insulin, or metformin\n* is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months\n* has undergone a surgical procedure within 4 weeks or has planned major surgery during the study\n* has a medical history of active liver disease\n* has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder\n* has a diagnosis of congestive heart failure with New York Heart Association Class III - IV cardiac status\n* has a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 90 mmHg\n* has human immunodeficiency virus (HIV)\n* has severe peripheral vascular disease\n* is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks\n* has a history of malignancy ≤ 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* has a clinically important hematological disorder (such as aplastic anemia,\n\nmyeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n* is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication\n* is a user of recreational or illicit drugs or has had a recent history of drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":null},{"groupId":"OG001","value":"-0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":null},{"groupId":"OG001","value":"-0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.9","spread":null},{"groupId":"OG001","value":"-21.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With One or More Adverse Events","description":"An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Medication Due to an AE","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":234},"commonTop":["Hypoglycaemia","Blood glucose increased","Upper respiratory tract infection"]}}}